About

Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, often resistant to chemotherapy and typically treated with surgery when possible. Neladalkib is a targeted drug that blocks the ALK protein—a key driver of tumor growth—while also reaching cancer cells in the brain. By precisely inhibiting ALK throughout the body, this drug could help slow disease progression in patients whose tumors have stopped responding to earlier treatments.